AP NEWS

Global Immune Repertoire Sequencing Market to Surpass US$ 185 Million by 2026 – Coherent Market Insights

February 8, 2019

SEATTLE--(BUSINESS WIRE)--Feb 8, 2019--According to Coherent Market Insights, the global immune repertoire sequencing market was valued at US$ 114.3 million in 2017, and is projected to exhibit a CAGR of 5.6% over the forecast period (2018–2026).

Key Trends and Analysis of the Immune Repertoire Sequencing Market:

Discovery of various innovative disease-related biomarkers using next-gen immune repertoire sequencing data is expected to fuel growth of the immune repertoire sequencing market, globally. For instance, Haystack Heuristic biomarker for autoimmune disease is an algorithm customized to computationally extract disease-associated motifs from next-generation-sequenced repertoires for contrasting disease and healthy subject.

Request Sample Copy of this Report @

Growing healthcare infrastructure in various emerging economies such as Japan and China are expected to fuel growth of the global immune repertoire sequencing market. Developments by China and Japan for the integration of new technologies in biomedical research, including technological advancements in genome sequencing, are expected to boost growth of the immune repertoire sequencing market.

High throughput immune repertoire sequencing is promising new statistical diagnostic tools enabling large-scale characterization of functional antibody repertoires. These repertoires are new methods for understanding protective and pathogenic immune responses of medicine and biology of vaccine development to target specific cancer cells and development of immune therapy against cancer progression. Therefore, high throughput sequencing of both immunoglobulin and TCR sequences create numerous opportunities for growth of the immune repertoire sequencing market.

Technological advancements such as high-throughput screening, new software-based platforms, and high adoption rate of immune repertoire sequencing with new technology are factors expected to drive growth of the global market. For instance, Illumina, Inc. introduced the NovaSeq Series, a new and scalable sequencing architecture, designed to allow researchers to access next-generation sequencing technology and conduct large-scale genomics projects with greater sample volumes.

Key players are launching innovative products in the market, in order to increase its market share. Such innovative products are addressing various clinical needs of patients, which is expected to create conducive environment for growth of the immune repertoire sequencing market. For instance, in 2016, ArcherDX, Inc., a U.S.-based company, expanded its product portfolio with the launch of Archer Immunoverse immune repertoire sequencing assays at the American Society of Hematology (ASH). In 2017, ArcherDX, Inc. launched Archer Immunoverse B Cell Receptor (BCR) assays to characterize the human B cell repertoire.

To know the latest trends and insights prevalent in this market, click the link below:

Key Market Takeaways:

The global immune repertoire sequencing market is expected to exhibit CAGR of 5.6% during the forecast period (2018–2026). Major players in the market are involved in strategic partnership and collaborations, in order to develop immune repertoire sequencing services to customers. For instance, in March 2018, ArcherDX Inc. and Ambry Genetics entered into strategic partnership to provide immune repertoire sequencing services to biopharmaceutical customers. As per the partnership agreement, Ambry Genetics will use ArcherDX’s Immunoverse and VariantPlex next-generation sequencing assays for immune repertoire sequencing. Key players operating in the global immune repertoire sequencing market include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190208005182/en/

CONTACT: Mr. Shah

Coherent Market Insights

1001 4th Ave.

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS

SOURCE: Coherent Market Insights

Copyright Business Wire 2019.

PUB: 02/08/2019 08:35 AM/DISC: 02/08/2019 08:35 AM

http://www.businesswire.com/news/home/20190208005182/en

AP RADIO
Update hourly